Hikma Pharmaceuticals PLC (HIK.L)
| Previous close | 1,960.00 |
| Open | 1,994.00 |
| Bid | 1,974.00 x 0 |
| Ask | 1,976.00 x 0 |
| Day's range | 1,958.48 - 2,000.00 |
| 52-week range | 1,711.00 - 2,222.00 |
| Volume | |
| Avg. volume | 624,967 |
| Market cap | 4.38B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 29.03 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.57 (2.93%) |
| Ex-dividend date | 21 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.
- PR Newswire
Hikma announces US launch of COMBOGESIC® IV
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.
- Business Wire
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
PALO ALTO, Calif., January 08, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa (MENA).
